CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing selective internal radiation therapy

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 1, 2013, Pages 63-66

  Fahmueller, Yvonne Nadine ^a   Nagel, Dorothea ^a   Hoffmann, Ralf Thorsten ^a,b   Tatsch, Klaus ^a,c   Jakobs, Tobias ^a,d   Stieber, Petra ^a   Holdenrieder, Stefan ^a,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Municipal Hospital of Karlsruhe Inc   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Biomarker; Breast cancer; CA 15 3; Selective Internal Radiation Therapy (SIRT)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLINESTERASE; CYTOKERATIN 19 FRAGMENT; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; LIVER METASTASIS; PILOT STUDY; PREDICTIVE VALUE; SELECTIVE INTERNAL RADIATION THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MUCIN-1; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871859741     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP51063     Document Type: Article

References (7)

1. Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, Robertson JF, Evans AJ. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003; 89: 284-290. doi:10.1038/sj.bjc.6601038 PubMed (Pubitemid 36976317)
2. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radio-embolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010; 40: 105-121. doi:10.1053/j.semnuclmed.2009.11.001 PubMed
3. Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008; 48: 839-849. PubMed doi:10.1007/s00117-008-1730-x
4. Dunfee BL, Riaz A, Lewandowski RJ, Ibrahim S, Mulcahy MF, Ryu RK, Atassi B, Sato KT, Newman S, Omary RA, Benson A III, Salem R. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol. 2010; 21: 90-95. doi:10.1016/j.jvir.2009.09.011 PubMed
5. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer. 2012; 12: 5. doi:10.1186/1471-2407-12-5 PubMed
6. Cianni R, Urigo C, Notarianni E, Saltarelli A, Salvatori R, Pasqualini V, Dornbusch T, Cortesi E. Selective internal radiation therapy with SIRspheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol. 2009; 32: 1179-1186. doi:10.1007/s00270-009-9658-8 PubMed
7. Cade D. FOLFOX plus SIR-spheres microspheres versus FOLFOX alone in patients with liver metastases from primary colorectal cancer (SIRFLOX). Clinical trials identification number NCT00724503. http://clinicaltrials.gov.